Solriamfetol Titration and AdministRaTion (START) in Patients with Obstructive Sleep Apnea: A Retrospective Chart Review and Hypothetical Patient Scenario

INTRODUCTION: Solriamfetol (Sunosi™), a dopamine/norepinephrine reuptake inhibitor, is approved (USA and EU) to treat excessive daytime sleepiness (EDS) in adults with obstructive sleep apnea (OSA) (37.5–150 mg/day). Real-world research on solriamfetol initiation is limited. The objective of this st...

Descripción completa

Detalles Bibliográficos
Autores principales: Singh, Haramandeep, Hyman, Danielle, Parks, Gregory S., Chen, Abby, Foley, Catherine, Baldys, Beth, Ito, Diane, Thorpy, Michael J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2022
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9402730/
https://www.ncbi.nlm.nih.gov/pubmed/35927541
http://dx.doi.org/10.1007/s12325-022-02249-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9402730/
https://www.ncbi.nlm.nih.gov/pubmed/35927541
http://dx.doi.org/10.1007/s12325-022-02249-4

Ejemplares similares